Multinational phase 3 study of atezolizumab after adjuvant chemotherapy for resected stage IB-IIIA NSCLC

Adjuvant platinum-based chemotherapy provides only a modest survival benefit in fully-resected, high-risk, early-stage NSCLC. The multinational phase 3 IMpower010 study compared atezolizumab versus best supportive care after adjuvant chemotherapy for resected stage IB-IIIA NSCLC. The median DFS was significantly longer in the atezolizumab group compared with the BSC group. The safety profile was consistent with prior experience of atezolizumab monotherapy across indications and lines of therapy.